Abstract

NETARSUDIL 0.02% AS A MONOTHERAPY IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA AT A TERTIARY HEALTH CARE CENTRE IN CENTRAL INDIA: A RANDOMIZED CLINICAL TRIAL

Mayuri Shamrao Rathod*, Kavita A. Dhabarde, Shubham Subhash Gattani, Arun Mohan Lalge, Aayushi Ramesh Daga and Shweta Sanjiv Chopade

.

Abstract

Objectives: To evaluate the ocular hypotensive efficacy and safety of netarsudil 0.02% ophthalmic solution as a monotherapy in patients with primary open-angle glaucoma at a tertiary health care centre. Methods: In our randomized prospective interventional study, we enrolled 25 patients with primary open-angle glaucoma who presented to us in eye outpatient department. Patients were given netarsudil 0.02% ophthalmic solution at the baseline visit at the recommended once-daily dosage. Best-corrected visual acuity, fundus examination, intraocular pressure (IOP), and any adverse events were noted in follow-up visits, at day one, two weeks, four weeks, six weeks and three months. Results: Out of 25 patients, 24 patients were included in the study as one patient experienced conjunctival hyperemia and was excluded from the study. The mean IOP at baseline (before starting netarsudil eye drop) in the right eye was 23.66 ± 3.19 mmHg and in the left eye was 23.70 ± 3.83 mmHg. The IOP was measured after two Weeks, four weeks, six weeks and three months. The mean IOP at the three-month follow-up visit in the right eye was 18.04 ± 3.15 mmHg, and in the left eye was 18.33 ± 3.49 mmHg. In our study, the reduction in intraocular pressure was statistically significant (p-value

Keywords: Netarsudil, primary open angle glaucoma, intraocular pressure, Rock inhibitor, norepinephrine transport (NET) inhibitor, monotherapy.